Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression Up to 52 Weeks: An Overview From Secukinumab Phase 3 Clinical Trials
Document Type
Abstract
Publication Date
October 2017
Journal Title
Arthritis & Rheumatology
Department
Dermatology
Recommended Citation
Mease, P., Lebwohl, M., Gilloteau, I., Fox, T., Oliver, J., Jugl, S., & Gottlieb, A. (2017). Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression Up to 52 Weeks: An Overview From Secukinumab Phase 3 Clinical Trials. Arthritis & Rheumatology, 69 (Suppl 10), 607. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/99
COinS
